{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:55:33Z","timestamp":1790834133561,"version":"4.1.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172547, 81602355"],"award-info":[{"award-number":["81172547, 81602355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00377","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T04:20:11Z","timestamp":1519705211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Valproic Acid Combined with Zoledronate Enhance \u03b3\u03b4 T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates"],"prefix":"10.3389","volume":"9","author":[{"given":"Shengdong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deting","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangsiyuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4419-0284-9_4","article-title":"Osteosarcoma multidisciplinary approach to the management from the pathologist\u2019s perspective","volume":"152","author":"Raymond","year":"2009","journal-title":"Cancer Treat Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.11799","article-title":"Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy","volume":"98","author":"Hawkins","year":"2003","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2008.16.2305","article-title":"Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients","volume":"27","author":"Bielack","year":"2009","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/978-1-4419-0284-9_25","article-title":"Is there a role for immunotherapy in osteosarcoma?","volume":"152","author":"Loeb","year":"2009","journal-title":"Cancer Treat Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13684730310001977","article-title":"Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells","volume":"7","author":"Liebau","year":"2002","journal-title":"Cytokines Cell Mol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-3-319-04843-7_19","article-title":"Natural killer cells for osteosarcoma","volume":"804","author":"Tarek","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11999-010-1302-z","article-title":"Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma","volume":"468","author":"Kawano","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-9966-33-27","article-title":"Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma","volume":"33","author":"Pahl","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2016.00353","article-title":"T-cell-based immunotherapy for osteosarcoma: challenges and opportunities","volume":"7","author":"Wang","year":"2016","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-cell therapy for cancer","volume":"130","author":"Yang","year":"2016","journal-title":"Adv Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1189\/jlb.0613312","article-title":"At the bench: preclinical rationale for exploiting NK cells and gammadelta T lymphocytes for the treatment of high-risk leukemias","volume":"94","author":"Norell","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/1074-7613(95)90178-7","article-title":"Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells","volume":"3","author":"Morita","year":"1995","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"[gamma][delta] cells: a right time and a right place for a conserved third way of protection","volume":"18","author":"Hayday","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2007.11.005","article-title":"Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells","volume":"249","author":"Muraro","year":"2007","journal-title":"Cell Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.13423\/j.cnki.cjcmi.005670","article-title":"[gammadelta T cells stimulated by zoledronate kill osteosarcoma cells]","volume":"26","author":"Jiang","year":"2010","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.4049\/jimmunol.167.9.5092","article-title":"Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens","volume":"167","author":"Kato","year":"2001","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2016.11.013","article-title":"Adoptive transfer of ex vivo expanded Vgamma9Vdelta2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer","volume":"386","author":"Zysk","year":"2017","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2012.12.021","article-title":"Potent antitumor activity of zoledronic acid-induced Vgamma9Vdelta2 T cells against primary effusion lymphoma","volume":"331","author":"Goto","year":"2013","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.4049\/jimmunol.1002697","article-title":"Indirect stimulation of human Vgamma2Vdelta2 T cells through alterations in isoprenoid metabolism","volume":"187","author":"Wang","year":"2011","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.canlet.2014.11.030","article-title":"Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vgamma9Vdelta2 T cell cytotoxicity in PC-3 prostate cancer cells","volume":"357","author":"Arkko","year":"2015","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jor.21579","article-title":"Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cell-mediated cytotoxicity by zoledronate","volume":"30","author":"Li","year":"2012","journal-title":"J Orthop Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","article-title":"Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity","volume":"56","author":"Mattarollo","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2016.03.004","article-title":"Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells","volume":"375","author":"G\u00f6bel","year":"2016","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacety lase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jcb.20532","article-title":"Prospects: histone deacetylase inhibitors","volume":"96","author":"Dokmanovic","year":"2005","journal-title":"J Cell Biochem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1349-7006.2009.01439.x","article-title":"Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis","volume":"101","author":"Lu","year":"2010","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/leu.2008.354","article-title":"Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate","volume":"23","author":"Poggi","year":"2009","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1006088","DOI":"10.1080\/2162402X.2015.1006088","article-title":"gammadelta T cells and epigenetic drugs: a useful merger in cancer immunotherapy?","volume":"4","author":"Bhat","year":"2015","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"64743","DOI":"10.18632\/oncotarget.11462","article-title":"Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma\/delta T-cells","volume":"7","author":"Bhat","year":"2016","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.4049\/jimmunol.1300255","article-title":"Repeated systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells efficiently control tumor development in vivo","volume":"191","author":"Santolaria","year":"2013","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2013.08.042","article-title":"Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-kappaB pathway","volume":"342","author":"Zhao","year":"2014","journal-title":"Cancer Lett"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1604","DOI":"10.1038\/cddis.2014.543","article-title":"Celastrol induces apoptosis and autophagy via the ROS\/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study","volume":"6","author":"Li","year":"2015","journal-title":"Cell Death Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","article-title":"Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors","volume":"115","author":"Chou","year":"1981","journal-title":"Eur J Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","article-title":"Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners","volume":"7","author":"Okamoto","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cas.12124","article-title":"Comparison of gammadelta T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid","volume":"104","author":"Idrees","year":"2013","journal-title":"Cancer Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10555-009-9186-7","article-title":"Osteosarcoma treatment: state of the art","volume":"28","author":"Ta","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2015.07.042","article-title":"Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner","volume":"368","author":"Fernandez","year":"2015","journal-title":"Cancer Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/1078-0432.CCR-11-2277","article-title":"Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma","volume":"18","author":"Pahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.02.025","article-title":"Interleukin 32, inflammation and cancer","volume":"174","author":"Hong","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.18632\/oncotarget.2505","article-title":"Induction of a specific CD8+ T-cell response to cancer\/testis antigens by demethylating pre-treatment against osteosarcoma","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.4049\/jimmunol.1303343","article-title":"Type I IFNs and IL-18 regulate the antiviral response of primary human gammadelta T cells against dendritic cells infected with dengue virus","volume":"194","author":"Tsai","year":"2015","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00262-017-2011-1","article-title":"Zoledronic acid renders human M1 and M2 macrophages susceptible to Vdelta2+ gammadelta T cell cytotoxicity in a perforin-dependent manner","volume":"66","author":"Fowler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.4049\/jimmunol.1003599","article-title":"Rapid and transient activation of gammadelta T cells to IFN-gamma production, NK cell-like killing, and antigen processing during acute virus infection","volume":"186","author":"Toka","year":"2011","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","article-title":"Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-06-3069","article-title":"Perspectives of gammadelta T cells in tumor immunology","volume":"67","author":"Kabelitz","year":"2007","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bcp.2015.04.009","article-title":"In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors","volume":"96","author":"Reilly","year":"2015","journal-title":"Biochem Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T04:20:14Z","timestamp":1519705214000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2018.00377"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00377","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"article-number":"377"}}